Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
120,494,078
-
Total 13F shares
-
51,462,756
-
Share change
-
+1,403,448
-
Total reported value
-
$112,702,942
-
Price per share
-
$2.19
-
Number of holders
-
47
-
Value change
-
+$3,027,391
-
Number of buys
-
31
-
Number of sells
-
6
Institutional Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) as of Q1 2025
As of 31 Mar 2025,
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) was held by
47 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
51,462,756 shares.
The largest 10 holders included
Sands Capital Ventures, LLC, Soleus Capital Management, L.P., Fairmount Funds Management LLC, PERCEPTIVE ADVISORS LLC, COMMODORE CAPITAL LP, ADAR1 Capital Management, LLC, VANGUARD GROUP INC, Nantahala Capital Management, LLC, Blackstone Inc., and Stonepine Capital Management, LLC.
This page lists
47
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.